RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.5 EUR | +0.30% |
|
+0.90% | +3.42% |
| 08:24am | Mib in green; UniCredit and MPS boost profit | AN |
| 05-06 | Mib caresses 34,000; Amplifon bullish | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
08/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
50.35
EUR
Average target price
52.14
EUR
Spread / Average Target
+3.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.42% | 11.17B | |
| +32.95% | 690B | |
| +26.43% | 546B | |
| -4.89% | 358B | |
| +18.17% | 323B | |
| +4.87% | 287B | |
| +14.32% | 235B | |
| +5.79% | 199B | |
| -9.49% | 195B | |
| +4.76% | 161B |
- Stock Market
- Equities
- REC Stock
- News Recordati
- Recordati : Italy's Recordati Commences Process to Reinforce Governance
